Immunocore Holdings plc Estimated Financial Effect Of Contingent Liabilities
Immunocore Holdings plc (IMCR) had Estimated Financial Effect Of Contingent Liabilities of GBP 1.13 million as of 2022-12-31, per its 20-F filed 2023-03-01.
Discontinued › Notes
ifrs-full:EstimatedFinancialEffectOfContingentLiabilities · last filed 2023-03-01
- 2022-12-31: Estimated Financial Effect Of Contingent Liabilities 1.13M GBP.
- 2021-12-31: Estimated Financial Effect Of Contingent Liabilities 1.12M GBP.
- 2020-12-31: Estimated Financial Effect Of Contingent Liabilities 6.57M GBP.
- 2019-12-31: Estimated Financial Effect Of Contingent Liabilities 7.04M GBP.
| Period end | Estimated Financial Effect Of Contingent Liabilities |
|---|---|
| 2022-12-31 | 1.13M GBP 20-F · filed 2023-03-01 |
| 2021-12-31 | 1.12M GBP 20-F · filed 2023-03-01 |
| 2020-12-31 | 6.57M GBP 20-F · filed 2022-03-03 |
| 2019-12-31 | 7.04M GBP 20-F · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |